Phase I Dose Finding Study of the Orally Bioavailable Platinum Analog Satraplatin in Combination With Abraxane (Paclitaxel Protein-bound Particles) in Advanced Cancers
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2013
At a glance
- Drugs Paclitaxel (Primary) ; Satraplatin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 22 Jan 2013 Drug company changed from GPC Biotech to Agennix as reported by ClinicalTrials.gov.
- 22 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jun 2009 Planned end date changed from 1 Dec 2009 to 1 Jun 2010 as reported by ClinicalTrials.gov.